All In Biotech

NDA 050796 · B Braun

Ceftriaxone and Dextrose In Duplex Container

Ceftriaxone Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Apr 20, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

218

68 Phase 3, 21 recruiting

FAERS reports

33,350

31,411 serious, 5,724 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 13, 2022.

Ceftriaxone for Injection and Dextrose Injection is indicated for the treatment of the following infections when caused by susceptible bacteria. Ceftriaxone for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria: Lower Respiratory Tract Infections ( 1.1 ); Skin and Skin Structure Infections ( 1.2 ); Complicated and Uncomplicated Urinary Tract Infections ( 1.3 ); Pelvic Inflammatory Disease ( 1.4 ); Bacterial Septicemia ( 1.5 ); Bone and Joint Infections ( 1.6 ); Intra-abdominal Infections ( 1.7 ); Meningitis ( 1.8 ); and Surgical Prophylaxis ( 1.9 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and Dextrose Injection and other antibacterial drugs, Ceftriaxone for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Lower Respiratory Tract Infections Lower respiratory tract infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens . 1.2 Skin and Skin Structure Infections Skin and skin structure infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii The efficacy for these organisms in this organ system were studied in fewer than ten infections. , Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter...

Mechanism: Ceftriaxone is an antibacterial drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 20, 2005 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
2 products under this application
  • CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER · CEFTRIAXONE SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER · CEFTRIAXONE SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ceftriaxone" as an intervention, any sponsor and status, largest first.

All 218 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use3,609
  • drug ineffective3,316
  • pyrexia1,775
  • acute kidney injury1,662
  • condition aggravated1,427
  • dyspnoea1,143
  • pneumonia1,101
  • drug interaction1,057
  • vomiting1,039
  • nausea996
  • drug reaction with eosinophilia and systemic symptoms940
  • diarrhoea921

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004136
2005226
2006237
2007252
2008360
2009411
2010375
2011507
2012698
2013790
20141,024
2015969
20161,254
20171,422
20182,080
20192,192
20203,821
20213,621
20222,871
20232,637
20242,813
20252,709
20261,944

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,139 on PubMed

Sponsor: B Braun

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.